KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Change in Accured Expenses (2016 - 2025)

Exact Sciences (EXAS) has disclosed Change in Accured Expenses for 14 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 707.63% to $8.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.2 million, a 153.66% decrease, with the full-year FY2025 number at -$5.2 million, down 153.66% from a year prior.
  • Change in Accured Expenses was $8.4 million for Q4 2025 at Exact Sciences, up from -$626000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $12.8 million in Q2 2024 to a low of -$7.2 million in Q2 2025.
  • A 4-year average of $594750.0 and a median of -$893500.0 in 2023 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 4750.86% in 2023; the steepest drop was 338.88% in 2023.
  • Exact Sciences' Change in Accured Expenses stood at $1.3 million in 2022, then surged by 502.77% to $7.6 million in 2023, then plummeted by 118.26% to -$1.4 million in 2024, then surged by 707.63% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Change in Accured Expenses are $8.4 million (Q4 2025), -$626000.0 (Q3 2025), and -$7.2 million (Q2 2025).